EMA says data behind Amgen's Tavneos were
European regulators on Thursday detailed their skepticism of data behind Amgen’s rare disease drug Tavneos, explaining a decision last week to pull the drug from …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the…
NEJM retracts pivotal data behind Amgen's Tavneos after FDA probe finds results for 9 patients re-evaluated post-unblinding; EU…
With the European Union formally reversing its marketing authorization for rare disease med Tavneos last week, regulators from…
The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma…
Amgen submitted new analyses to FDA supporting Tavneos staying on market, disputing data manipulation claims.
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
